Sarepta (SRPT) Trades Higher on Eteplirsen Phase II Update, Analyst Comments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Sarepta (SRPT) Analysts Split on Accelerated Eteplirsen Approval - Barron's
March 25, 2013 2:51 PM EDTSarepta Therapeutics (Nasdaq: SRPT) is comfortably in positive territory Monday following positive commentary in Barron's over the weekend.
Traders and investors are watching Sarepta as the FDA nears a decision on its Duchenne muscular dystrophy (DMD) drug, eteplirsen. Shares of Sarepta have traded strong since positive results from a Phase 2B trial on DMD were released last October.
... More
Sarepta (SRPT) Analysts Split on Accelerated Eteplirsen Approval - Barron's
March 25, 2013 2:51 PM EDTSarepta Therapeutics (Nasdaq: SRPT) is comfortably in positive territory Monday following positive commentary in Barron's over the weekend.
Traders and investors are watching Sarepta as the FDA nears a decision on its Duchenne muscular dystrophy (DMD) drug, eteplirsen. Shares of Sarepta have traded strong since positive results from a Phase 2B trial on DMD were released last October.
... More
